The 14th World Conference on Lung Cancer (WCLC 2011) was held in Amsterdam, The Netherlands on 3–7 July.
At WCLC 2011 a CME-accredited symposium (supported by AstraZeneca) was held, entitled ‘EGFR mutation-positive advanced NSCLC: optimising treatment sequences based on molecular biology’.
The symposium was presented by an international panel of leading oncologists:
- Egbert Smit (The Netherlands; co-chair)
- Tony Mok (Hong Kong; co-chair)
- Pasi Jänne (USA)
- Jean-Yves Douillard (France)
With recent advances in molecular biology and therapies targeted to specific molecular subtypes of advanced NSCLC, consideration of the sequence of treatments for patients is becoming increasingly important. The faculty discussed the management of patients with EGFR mutation-positive advanced NSCLC in the first-line setting and the importance of testing for EGFR mutations. The molecular biology of EGFR mutation-positive tumours was discussed moving on to an exploration of how new therapeutic targets may be identified based on a broader understanding of advanced NSCLC. Evidence and clinical experience were presented on treating patients with EGFR mutation-positive advanced NSCLC after they have received first-line EGFR TKI treatment. Finally, interactive case studies were presented to assess the audience’s response to real-world clinical situations.
Click on the image below to view the full video and slides of the symposium.
Please note that this symposium contains information about the first-line use of gefitinib in EGFR mutation-positive advanced NSCLC. Gefitinib product licences vary from country to country and not all licences include first-line use in EGFR mutation-positive advanced NSCLC. Please consult your local prescribing information.
Egbert Smit and Tony Mok: Conference Highlights
Below is a video featuring the two co-chairs of the symposium discussing the clinical implications of the information presented.